Literature DB >> 10604893

Comparative effects of tissue plasminogen activator, streptokinase, and staphylokinase on cerebral ischemic infarction and pulmonary clot lysis in hamster models.

N Nagai1, I Vanlinthout, D Collen.   

Abstract

BACKGROUND: The effects of alteplase (rtPA), streptokinase, and staphylokinase (rSak) on focal cerebral ischemia (FCI) and on pulmonary clot lysis (PCL) were studied in hamsters. METHODS AND
RESULTS: ++FCI was produced by ligation of the left middle cerebral artery (MCA) and common carotid artery (CCA) and a 10-minute occlusion of the right CCA. FCI was measured after 24 hours by 2,3, 5-triphenyltetrazolium chloride staining. (125)I-fibrin-labeled plasma clots were injected via the jugular vein, and clot lysis was determined from residual radioactivity at 90 minutes. Study drugs were given intravenously over 60 minutes. FCI increased from 1.2 (0. 27 to 2.3) mm(3) (median and 17th to 83rd percentile range, n=24) in controls to 19 to 27 mm(3) with thrombolytic agent, with maximal rates at 0.13+/-0.05 mg/kg rtPA, 0.23+/-0.09 mg/kg streptokinase, and 0.037+/-0.025 mg/kg rSak. PCL increased from 18+/-2% (mean+/-SEM, n=27) in controls to approximately 85% with thrombolytics, with maximal rates at 0.12+/-0.03 mg/kg rtPA, 0.17+/-0.05 mg/kg streptokinase, and 0.018+/-0.002 mg/kg rSak. All agents caused maximal FCI and PCL rates at similar doses without alpha(2)-antiplasmin and fibrinogen depletion. Injection of 6 mg/kg human plasminogen combined with streptokinase caused a "systemic fibrinolytic state" with fibrinogen depletion. Maximal rates of FCI were obtained with 0.097+/-0.077 mg/kg streptokinase (P=0.26 versus streptokinase alone) and of PCL with 0.010+/-0.002 mg/kg (P=0.006 versus streptokinase alone).
CONCLUSIONS: Thrombolytic agents cause similar dose-related extension of FCI after MCA ligation and PCL, irrespective of the agent or systemic plasmin generation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10604893     DOI: 10.1161/01.cir.100.25.2541

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  12 in total

1.  An activated protein C analog with reduced anticoagulant activity extends the therapeutic window of tissue plasminogen activator for ischemic stroke in rodents.

Authors:  Yaoming Wang; Zhenggang Zhang; Nienwen Chow; Thomas P Davis; John H Griffin; Michael Chopp; Berislav V Zlokovic
Journal:  Stroke       Date:  2012-07-17       Impact factor: 7.914

Review 2.  α2-Antiplasmin: New Insights and Opportunities for Ischemic Stroke.

Authors:  Guy L Reed; Aiilyan K Houng; Satish Singh; Dong Wang
Journal:  Semin Thromb Hemost       Date:  2016-07-29       Impact factor: 4.180

Review 3.  Can the time window for administration of thrombolytics in stroke be increased?

Authors:  Geoffrey A Donnan; David W Howells; Romesh Markus; Danilo Toni; Stephen M Davis
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 4.  Stroke, Vascular Dementia, and Alzheimer's Disease: Molecular Links.

Authors:  Murali Vijayan; P Hemachandra Reddy
Journal:  J Alzheimers Dis       Date:  2016-09-06       Impact factor: 4.472

5.  VEGF-B inhibits apoptosis via VEGFR-1-mediated suppression of the expression of BH3-only protein genes in mice and rats.

Authors:  Yang Li; Fan Zhang; Nobuo Nagai; Zhongshu Tang; Shuihua Zhang; Pierre Scotney; Johan Lennartsson; Chaoyong Zhu; Yi Qu; Changge Fang; Jianyuan Hua; Osamu Matsuo; Guo-Hua Fong; Hao Ding; Yihai Cao; Kevin G Becker; Andrew Nash; Carl-Henrik Heldin; Xuri Li
Journal:  J Clin Invest       Date:  2008-03       Impact factor: 14.808

6.  Protein S blocks the extrinsic apoptotic cascade in tissue plasminogen activator/N-methyl D-aspartate-treated neurons via Tyro3-Akt-FKHRL1 signaling pathway.

Authors:  Huang Guo; Theresa M Barrett; Zhihui Zhong; José A Fernández; John H Griffin; Robert S Freeman; Berislav V Zlokovic
Journal:  Mol Neurodegener       Date:  2011-02-03       Impact factor: 14.195

7.  Combined Treatment With 2-(2-Benzofu-Ranyl)-2-Imidazoline and Recombinant Tissue Plasminogen Activator Protects Blood-Brain Barrier Integrity in a Rat Model of Embolic Middle Cerebral Artery Occlusion.

Authors:  Linlei Zhang; Shasha Xu; Xiaoxiao Wu; Jiaou Chen; Xiaoling Guo; Yungang Cao; Zheng Zhang; Jueyue Yan; Jianhua Cheng; Zhao Han
Journal:  Front Pharmacol       Date:  2020-06-12       Impact factor: 5.810

8.  Increase in blood-brain barrier permeability does not directly induce neuronal death but may accelerate ischemic neuronal damage.

Authors:  Chiemi Ohmori; Yusuke Sakai; Yasuki Matano; Yasuhiro Suzuki; Kazuo Umemura; Nobuo Nagai
Journal:  Exp Anim       Date:  2018-05-28

9.  The role of TPA I/D and PAI-1 4G/5G polymorphisms in multiple sclerosis.

Authors:  Maja Zivković; Nada Starčević Čizmarević; Luca Lovrečić; Inge Klupka-Sarić; Aleksandra Stanković; Iva Gašparović; Polona Lavtar; Evica Dinčić; Ljiljana Stojković; Gorazd Rudolf; Saša Sega Jazbec; Olivio Perković; Osman Sinanović; Juraj Sepčić; Miljenko Kapović; Borut Peterlin; Smiljana Ristić
Journal:  Dis Markers       Date:  2014-04-16       Impact factor: 3.434

10.  Tissue Plasminogen Activator Neurotoxicity is Neutralized by Recombinant ADAMTS 13.

Authors:  Mengchen Fan; Haochen Xu; Lixiang Wang; Haiyu Luo; Ximin Zhu; Ping Cai; Lixiang Wei; Lu Lu; Yongliang Cao; Rong Ye; Wenying Fan; Bing-Qiao Zhao
Journal:  Sci Rep       Date:  2016-05-16       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.